Amneal Insider Trades: CEO Buchi Sells 20,445 Shares to Trust as Stock Slips Amid FDA‑Approved Generic Boom
Insider sell of 20,445 Amneal shares signals strategic rebalancing amid FDA approval of a high‑margin generic; investors eye long‑term upside.
3 minutes to read